Xtl Biopharmaceuticals (XTLB) Net Cash Flow (QoQ) (2009 - 2015)
Xtl Biopharmaceuticals (XTLB) Net Cash Flow (QoQ) (2009 - 2015) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 854.29% |
| Sep 30, 2015 | -116.53% |
| Dec 31, 2014 | 51.53% |
| Sep 30, 2014 | -643.33% |
| Jun 30, 2014 | 120.83% |
| Mar 31, 2014 | 77.73% |
| Dec 31, 2013 | -141.03% |
| Sep 30, 2013 | 575.98% |
| Jun 30, 2013 | -1,476.19% |
| Mar 31, 2013 | 96.02% |
| Dec 31, 2012 | -1,355.95% |
| Sep 30, 2012 | 104.35% |
| Jun 30, 2012 | -143.17% |
| Mar 31, 2012 | 691.79% |
| Dec 31, 2011 | -633.01% |
| Sep 30, 2011 | 68.40% |
| Jun 30, 2011 | 34.14% |
| Mar 31, 2011 | -53.25% |
| Dec 31, 2010 | -126.05% |
| Sep 30, 2010 | 1,187.72% |